<DOC>
	<DOCNO>NCT01353963</DOCNO>
	<brief_summary>This non-interventional study review safety data administration desvenlafaxine succinate among Filipino patient MDD VMS per usual clinical practice within first three year post commercial distribution .</brief_summary>
	<brief_title>Desvenlafaxine Succinate ( Pristiq ) : Postmarketing Surveillance Study Among Filipino Patients</brief_title>
	<detailed_description>post marketing surveillance none</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Patients diagnose major depressive disorder vasomotor symptom secondary menopause prescribe desvenlafaxine succinate Hypersensitivity desvenlafaxine succinate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>